We value your privacy. When visiting our website, please agree to the use of all cookies. For more information on how we process your personal data, please visit: Legal & Privacy

h1_banner_pc.jpg

About Us

Mission, Vision, Value

About Us

As a world-leading provider of glucose technology solutions, we leverage comprehensive capabilities across R&D, manufacturing, and sales. We specialize in core glucose monitoring technologies, supported by a strong R&D team and advanced production facilities to continuously break through technical barriers. Our high-quality products cater to both home and clinical settings. Through our global sales and service network, we provide reliable monitoring devices and integrated solutions to users and medical institutions worldwide, empowering diabetes management through technology.

  • img03.jpg
  • img04.jpg
  • img03.jpg
  • img04.jpg
  • Mission
    To Become a Leading Player in the Global Tier 1 Group
  • Vision
    Crafting Premier Monitoring Solutions for Diabetes and Long-term Health
  • Value
    Integrity; Accountability; Passion
    Urgency; Innovation; Inclusion

Internationally Certified for Quality

We maintain an unwavering commitment to bringing our customers more high-quality products.

    • 2.jpg
    • 3.jpg
    • 4.jpg
    • 2.jpg
    • 3.jpg
    • 4.jpg
    • 2.jpg
    • 3.jpg
    • 4.jpg
    • 2.jpg
    • 3.jpg
    • 4.jpg

Strategic Roadmap

  • Global Markets
  • Global R&D Network

Yuwell-POCTech's Milestones

  • 2026

    Anytime 4 Series and Anytime 5 Series CE MDR Approved

  • 2025

    Gen2 GDH BGM NMPA approved

    Anytime 4 and Anytime 5 NMPA approved

  • 2024

    Over 1 billion BGM test strips sold globally this year

    BGM 2024 GOD NMPA approved

    CT3 CE MDR approved

  • 2023

    BGM reaches over 60 countries and regions globally

    CT3 NMPA approved

  • 2022

    CT2A NMPA apporved

  • 2021

    CT2 NMPA approved

  • 2019

    Gen3 GOD BGM CE&NMPA approved

  • 2018

    Gen1 GDH BGM NMPA approved

  • 2017

    CT100B CE apporved

  • 2016

    Gen2 GOD BGM NMPA approved

    CT100A CE approved

  • 2012

    Gen1 GOD BGM NMPA approved

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2019
  • 2018
  • 2017
  • 2016
  • 2012

Our Future

We drive technological breakthroughs through continuous innovation and empower the entire glucose monitoring ecosystem with AI. Our goal is to provide global users with more precise, intelligent, and personalized health management solutions, as we strive to become the world's most trusted leader in glucose health.

h1background04.jpg